MEDI3726
Based on 1 Customer Validation
MEDI3726 (ADCT-401) is a prostate-specific membrane antigen (PSMA)-targeting antibody-drug conjugate (ADC), composed of LP Tesirine (HY-128952) and antibody J591 (HY-P991359). MEDI3726 binds PSMA’s extracellular domain, triggers endocytosis, undergoes lysosomal degradation to release a pyrrolobenzodiazepine warhead. MEDI3726 induces DNA crosslinking, DNA damage, cell death, cytotoxicity, and inhibits tumor growth in mouse xenograft models. MEDI3726 undergoes in vivo catabolism primarily via heavy-light chain dissociation, with minimal warhead deconjugation. MEDI3726 can be used for the research of metastatic castration-resistant prostate cancer and prostate cancers.
For research use only. We do not sell to patients.
- Purity : 99.80%
-
Storage:
-80°C, protect from light
Biological Activity
Description
In Vitro
MEDI3726 (ADCT-401) exhibits potent, specific cytotoxicity in PSMA-expressing prostate cancer cell lines, with greatly reduced activity in PSMA-negative prostate cancer cell lines[3].
MEDI3726 (0.2 μg/mL; 1 h) cross-reacts with human and cynomolgus monkey soluble PSMA with similar potency, but does not cross-react with rat soluble PSMA[4].
MEDI3726 (up to 7 days) remains stable and active at 37°C in PBS, human plasma, or cynomolgus monkey plasma[4].
MEDI3726 (5-7 days) potently and specifically kills PSMA-positive human prostate cancer cell lines LNCaP (IC50 = 0.02 nM), LNCaP C4-2 (IC50 = 0.06 nM), MDA PCa 2b (IC50 = 0.002 nM), and CWR22Rv1 (IC50 = 0.29 nM), but shows no targeted cytotoxicity in PSMA-negative PC-3 (IC50 = 29.3 nM) and DU145 cell lines (IC50 = 44.9 nM)[4].
MEDI3726 (24 h) is specifically internalized and trafficked to lysosomes in PSMA-positive LNCaP cells, but not in PSMA-negative PC-3 cells[4].
MEDI3726 (6 nM; 2 h treatment) induces persistent DNA interstrand crosslinks in PSMA-positive LNCaP cells, but does not induce significant DNA crosslinking in PSMA-negative PC-3 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MEDI3726 (0.33-1 mg/kg; i.v.; single dose) displays dose-dependent antitumor activity in mouseCWR22Rv1 castration-resistant prostate cancer xenografts[4].
MEDI3726 (0.33-1 mg/kg; i.v.; single dose) exhibits only limited antitumor activity in mouse PSMA-negative PC-3 prostate cancer xenografts at the 1 mg/kg single dose[4].
MEDI3726 (0.1-0.9 mg/kg; i.v.; once every 3 weeks; 3 doses) demonstrates dose-dependent, statistically significant antitumor activity in highly PSMA-positive LuCaP prostate cancer mosue PDX models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MF1 nude mice (male, 4-8 weeks old, 22.6-35.3 g) subcutaneously implanted with LNCaP human prostate cancer cells[4]
-
Dosage:0.11; 0.33; 1 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed dose-dependent antitumor activity.
Produced extended tumor stasis preceding regrowth with a single 1 mg/kg dose.
Increased time-to-endpoint survival significantly with a single 1 mg/kg dose compared with all other groups.
Associated with a statistically significant increase in animal survival at doses of 0.33 mg/kg and 1 mg/kg compared with the naked antibody group.
-
Animal Model:C.B-17 SCID mice (male, 10 weeks old, 18.6-27.2 g) subcutaneously implanted with . CWR22Rv1 cells[4]
-
Dosage:0.33; 1 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed dose-dependent antitumor activity.
Induced prolonged tumor regression of approximately 50 days with a single 1 mg/kg dose.
-
Animal Model:MF1 nude mcie (female, 11 weeks old, 17.5-27.6 g) subcutaneously implanted with PC-3 human prostate cancer tumor fragments[4]
-
Dosage:0.33; 1 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed limited antitumor activity at the highest tested dose of 1 mg/kg.
-
Animal Model:C.B-17/IcrHsd-Prkdcscid mice (male, 8-12 weeks old, 21.1-25.5 g) subcutaneously implanted with LuCaP human prostate cancer tumor fragments[4]
-
Dosage:0.1; 0.3; 0.9 mg/kg
-
Administration:i.v.; once every 3 weeks; 3 doses
-
Result:Showed dose-dependent antitumor activity.
Produced statistically significant responses.
Produced statistically significant tumor regression.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[MEDI3726]
-
Synonyms
ADCT-401
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. de Bono JS, et al. Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021;27(13):3602-3609. [Content Brief]
[2]. Huang Y, et al. Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate. Anal Chem. 2020;92(16):11135-11144. [Content Brief]
[4]. Cho S, et al. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Mol Cancer Ther. 2018;17(10):2176-2186. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- MEDI3726
- ADCT-401
- MEDI 3726
- MEDI-3726
- ADCT401
- ADCT 401
- Antibody-Drug Conjugates (ADCs)
- PSMA
- lysosomal degradation
- metastatic castration-resistant prostate cancer
- extracellular domain
- prostate-specific membrane antigen
- PSMA-positive cancer cells
- xenograft models
- endocytosis
- DNA crosslinking
- DNA damage
- pyrrolobenzodiazepine
- Inhibitor
- inhibitor
- inhibit